Dan Cohen's Location
Arlington, Virginia, United States, United States
About Dan Cohen
My 40+ years of executive leadership in government, economics, medicine, and business has culminated in a drive to create successful startups and portfolio companies that enhance medical technologies while bringing enhanced benefits to healthcare professionals and patients alike. My combination of skills and experience includes a strong track record of successful mergers and acquisitions, market financing, sales, and product development throughout the business landscape with executive leadership roles across multiple verticals.One key to my success is a financial background that helps leverage and build profitability with strong P&L responsibility. My career in politics and business, combined with my years of teaching both students and professionals has allowed me to quickly identify strengths in people, business, and technology. Knowing how to nurture and leverage those strengths is how to grow businesses that command market share, drive sales and grow profitability. PainScript is a SaaS technology that connects physicians and patients to drive care plan adherence and medication compliance while helping physicians understand a patient’s day-to-day clinical treatment patterns. But it doesn’t stop there. This technology provides immediate insights into potential adverse medication reactions and early warning of potential serious/adverse events (AEs/SAEs) – all designed to improve patient outcomes and reduce costs to the healthcare system. We strive to create winning situations for all parties with whom we do business. Our technology is replicable across multiple verticals, which is a driver that allows us to quickly grow our brand and presence nationwide.Our TACT (Telehealth And Compliance Technologies) platform is a thought leader in the telehealth sector and we seek to pioneer telehealth/telemedicine technologies that will be a change agent for the betterment of our healthcare industry. Our teams strive to continue to rethink and approach traditional solutions with a cutting-edge mindset that brings tremendous product capability and value to the marketplace.
Dan Cohen Work Experience Details
-
PresidentPumpkin Cay Association #8Arlington, Va, Us
-
President And Co-Founder, Secretary Of The Board Of DirectorsAdhere+ (Formerly Painscript) Jul 2019 - PresentWashington, District Of Columbia, UsAdhere+ is an investment stage, technology start-up designing simple to use expert systems that delivers a personalized healthcare pathway for physicians and their patients with a need for chronic care treatment. Our initial product offers pain relief, emotional recovery, and abstinence for chronic pain patients with opioid and other substance abuse problems. Recruited Board of Directors to lead PainScript effort to offer a personalized pathway to support chronic care interventions for patients suffering from opioid and substance abuse who are under the care of a psychiatrist.• Designed and developed all aspects of start-up operations, including the technology application to use a clinically validated, accessible and user-friendly digital platform to provide physician and patients daily, evidence-based telemedicine monitoring interventions to effectively improve health outcomes and reduce related healthcare costs.• Established foundational business for telehealth App-based Chronic Care Compliance SaaS start-up, leading to a successful acquisition in 19 months, resulting in ~$4.5million investment by Optimus Healthcare Services• Design and developed viable MVP product with vendor partner agreeing to an equity investment.• Beta trials to GTM in six months, current commercial sales meeting initial goals at five months – 50,000 currently completed patient records on a per patient/per month billing cycle.• Completed Board of Directors and Scientific Advisory Boards recruitment/management for all verticals -
PresidentPumpkin Cay Association #8 Mar 2019 - Present
-
Chair Of The Board Of DirectorsMedstar National Rehabilitation Network Mar 2007 - Nov 2022Washington , Dc, Us• Chair, Board of Directors, 2018 – present o Vice Chair 2011 - 2018o Nationally ranked $127m Acute Care Rehabilitation Hospital• Chair, Quality, Safety and Patient Affairs Committee (QSPAC)MEDSTAR Health• $6.5b, largest Mid-Atlantic acute care hospital system• Member, Corporate Strategic Planning Committee 2018 - 2021• Member, Quality, Safety and Professional Affairs Committee 2007 – 2018 -
PresidentOptimus Healthcare Mar 2021 - Sep 2022• Named President upon acquisition by holding company with executive responsibility to acquire and manage new portfolio companies in the healthcare/telehealth space -
Ad Forum ChairUs Abuse Deterrent Coalition 2013 - Jan 2021US Abuse Deterrent Coalition, is a Public Policy “talk group” of over 20 ADF manufacturers, patient advocates and related organizations seeking to expand access to ADF technologies. The coalition provides a unified voice for legislative and regulatory initiatives that support the required use of abuse deterrent formulations for prescription drugs that have a high potential for abuse, especially opioids. Abuse deterrent formulations can also play a positive role in combating the growing problem of Schedule II stimulant prescription drug abuse, such as ADD and ADHD medication. Although there are many efforts through law enforcement, education, rehabilitation and regulation to curb the abuse of prescription drugs, the problem continues to grow. A comprehensive approach is needed to combat prescription pain medication abuse while still maintaining access for pain patients who need them and ADFs are another valuable tool in that effort.
-
Executive Vice President, Government & Public RelationsKempharm, Inc. Apr 2016 - Sep 2018Celebration, Fl, UsMember of executive management team, responsible for leading public policy and corporate communications strategies. • Designed and led successful effort resulting in US Food and Drug Administration (FDA) opioid product approval following an unsuccessful AdComm and failure to meet prespecified primary efficacy trial endpoints.• Managed all aspect of corporate public engagement with general and specialty media, SEC communications, investor meetings and public statements/releases.• Led design and develop of kempharm.com and related social media and collateral.• Served on multiply industry panels related to reimbursement, product approvals and industry standards.• Corporate spokesman, created modern Corporate website and structured social media platforms.• Frequent public speaker at industry conferences and with news media. -
Senior Vice President Of Government Relations And Health PolicyEnteromedics Mar 2008 - May 2016San Clemente, Ca, UsPublic policy and governmental regulatory relations for early-stage medical device company. • Designed and led successful campaign resulting in US FDA device approval, second unique obesity device approved since 2001, despite failure to meet prespecified Clinical Trial end points• Implemented initial national reimbursement effort for company product. • Managed and coordinated all aspects (physician prep, media, and third-party support) of successful FDA Advisory Panel preparation for product approval in June 2014. -
Head Of North American Government Affairs -- ConsultantGrünenthal Usa 2013 - Apr 2016Led for public policy and governmental regulatory relations in Washington, D.C. for Grünenthal USA, a biopharmaceutical company which has developed and commercialized Abuse Deterrence Formulations (ADF) for opioid analgesics.
-
Managing Director, Global Government RelationsThe Depository Trust & Clearing Corporation Jan 2011 - Dec 2012Responsible for an aggressive, proactive global government relations function. Managed seven direct and 23 indirect reports, with annual budget responsibilities of $8.1M.• Led successful tripartite negotiation between DTCC, Congress, and Plaintiffs Bar to preserve Article 8 related to the “Indirect Financial Holding System” of the Uniform Commercial Code related to Iranian assets held in the U.S., preserved victims’ rights and saved U.S. banking system/U.S. customers upwards of $2.4B.• Prepared, led and opened regulatory and legislative offices in Washington, D.C., Brussels, Belgium and Tokyo, Japan, creating government relation entities that allowed the company to establish a global derivative “Swap Data Repository” network.• Testified and/or presented in forums, on panels and lobbying situations in: Americas (US, Canada, Panama, Argentina); Asia (Singapore, Japan, Hong Kong, Taiwan); and Europe (UK, France, Belgium, Germany, Hungary, Poland, Czech Republic, Denmark, Italy, Spain).• Executive Director, DTCC PAC. Led all fundraising and political action initiatives of the DTCC Political Action Committee. Created company Political Action Committee (PAC). Raised over $425,000 in initial campaign cycle and hosted 31 coordinated events raising $1.04M in the first year.
-
Senior Vice President, Government RelationsInamed, A Division Of Allergan Corporation Mar 1999 - Apr 2009(Allergan acquired Inamed Corporation in 2006) Post-Merger Consultant, Allergan Corp. (2006 - 2009)Provided counsel on issues and on-going legislative strategies related to silicone gel-filled breast implants (SBI), laparoscopic adjustable gastric banding and hyaluronic acid gels: • Defeated Congressional efforts to reverse FDA approval of silicone gel-filled breast implants.• Managed Denmark-based SBI data registry for breast health outcomes.• Led effort to exempt medical devices containing cyclosiloxane from Environment Canada’s proposed risk management policy, preserving device sales of over $50M.V.P. Government Affairs and Investor Relations, Inamed Corp. (2003 - 2006) Consultant, Inamed Corp. (1999 - 2003)Led global public policy and served as public spokesman with national media and at investor conferences.• Led regulatory advisory panel presentation to earn re-approval of SBI for US market. Overturned 14-year market moratorium. Effort was a major contributor to company’s unsolicited acquisition by Allergan Corporation for 17% premium over a pre-negotiated merger with Medicis Corporation (and 76% premium over pre-device-approval market valuations).• Led successful effort with Health Canada and the Parliament to restore silicone gel-filled breast implants to that market. Approval increased market share to 50% of Canadian market.• Designed, coordinated and led effort to gain National Coverage Determination for Bariatric procedures and inclusion of Inamed’s laparoscopic adjustable gastric banding (LAGB). Implemented similar effort with Health Canada. LAGB grew to 50% of the North American market as the result of the coverage determination.• Corporate spokesman, “Buy/Sell Side” investor conduit, earnings call/Reg. FD participant and member of the 2005/06 merger negotiating team with Medicis Corporation.
-
Senior Vice PresidentUs Oncology Jan 2006 - Mar 2009The Woodlands, Tx, UsLed State and Federal public policy for the largest oncology physician provider. Managed 7 direct and 35 indirect support staff and consultants.• Implemented national effort to reverse and ultimately mitigate impact of federal effort to restrict use of Erythropoiesis-Stimulating Agents for cancer patients. Effort modified initial policy restrictions and restored annualized $35Min projected losses.• Led federal effort to reverse and ultimately prevent reductions in reimbursement for diagnostic and treatment imaging for IMRT, IGRT, CT-Angiogram and PET-CT, saving $10-12M annually.• Managed campaign in Washington State to adopt business and occupancy tax laws amendments to preference physician offices. Annualized tax savings to three state practice groups of $1M per year for a ten year period.• Led efforts to prevent punitive tax policies and/or service restrictions in Maryland, Minnesota, Arizona, Texas, Florida, Virginia, North and South Carolina and Ohio. • Functioned as corporate spokesman on government relations with national and industry specific media.• Executive Director, USON Good Government Committee PAC. Led all fundraising and political action initiatives of the USON Good Government Committee. Grew PAC participation from $200,000 to $1.2M in one campaign cycle. Implemented coordinated events strategy that grew political action from $25,000 to $1.163M over the same period. -
Principal, Government Relations & Crisis ManagementLoeffler, Jonas And Tuggey, Llp Jan 1994 - Mar 2003Served as consultant/lobbyist, with an expertise in crisis management, for corporations including:Citibank/Citigroup• Managed political relationship in the Travelers merger creating Citigroup.CTIA – The Wireless Association• Led relationship efforts on Spectrum sales with Congressional LeadershipEdison Electric InstituteHong Kong Economic & Trade Office• Led Congressional delegations to Hong Kong and Guangzhou, China.• Managed Congressional relationships for Hong Kong’s transition from British to Chinese rule.Investment Company Institute• Protected company from Chairman of the Financial Services Committee • Managed aspects of Company legislative initiative for financial industry fair disclosure legislation.Motorola• Led company legislative outreach on Iridium project.Nuclear Energy InstitutePurdue Pharma• Led, created and implemented long-term (4 year) regulatory and legislative crisis management plan to combat effort by the DEA to remove OxyContin, a schedule II pain reliever, from the prescription market. Plan ultimately saved $1.2B in annual sales.QualCOMMSouthwest Airlines• Maintained critical “Wright Restriction” at Love Field in Dallas, Texas.The Scooter Store• Retained counsel and crisis-managed Congressional investigation into Medicare billing practices.Westinghouse Electric• Worked on nuclear plant safety design team to develop strategic public policy agenda.
-
Senior Legislative LiasionAmerica Israel Public Affairs Committee (Aipac) 1985 - 1993Washington, Dc, UsSenior Legislative Liaison (Defense and Intelligence Lobbyist) -
Legislative DirectorCongressman Joseph M. Mcdade Jan 1983 - Dec 1985
-
Senior Legislative LiasionCongressman Edward F. Weber Mar 1981 - Dec 1982
-
FundraiserSenator Roger Jepsen Jan 1981 - Mar 1981
-
Field RepresentativeSenator Charles Grassley May 1980 - Jan 1981
-
Iowa Press Secretary/Field DirectorSenator Robert Dole For President Committee Apr 1979 - Feb 1980
Dan Cohen Education Details
-
Georgetown UniversityInternational Affairs -
Willamette UniversitySociology
Frequently Asked Questions about Dan Cohen
What company does Dan Cohen work for?
Dan Cohen works for Pumpkin Cay Association #8
What is Dan Cohen's role at the current company?
Dan Cohen's current role is President.
What schools did Dan Cohen attend?
Dan Cohen attended Georgetown University, Willamette University.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial